UK markets closed

Virpax Pharmaceuticals, Inc. (VRPX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.8700-0.0200 (-0.69%)
At close: 04:00PM EST
2.8700 0.00 (0.00%)
After hours: 04:52PM EST
Full screen
Trade prices are not sourced from all markets
Previous close2.8900
Open2.8500
Bid2.7900 x 900
Ask2.8800 x 800
Day's range2.7900 - 2.9000
52-week range2.7900 - 36.0000
Volume150,597
Avg. volume945,355
Market cap33.622M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.9110
Earnings date18 May 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Virpax® Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference

    BERWYN, Pa., January 04, 2022--Virpax® Pharmaceuticals, Inc. ("Virpax"), a company specializing in product candidates for pain management, CNS disorders and anti-viral indications, today announced that it will be presenting virtually at the upcoming H.C. Wainwright event from Monday, January 10th through Thursday, January 13th starting at 7:00 a.m. ET. Anthony Mack, Chairman & CEO of Virpax, will be giving the presentation. Management will also be hosting virtual one-on-one meetings on Monday, J

  • Business Wire

    Virpax Pharmaceuticals Recaps Milestones and Highlights Product Portfolio

    BERWYN, Pa., December 28, 2021--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX) achieved significant milestones relating to its pipeline of product candidates as of the end of 2021, which are summarized below.

  • Business Wire

    Virpax Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm™ for Pain Associated with Osteoarthritis of the Knee

    BERWYN, Pa., December 20, 2021--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., a leading clinical trial services company, for a First in Human study investigating Epoladerm™ for pain associated with osteoarthritis of the knee. The study will take place in Canada with a CTA filing and en